Back to Search Start Over

In Vivo PET Imaging of Monocytes Labeled with [Zr-89]Zr-PLGA-NH2 Nanoparticles in Tumor and Staphylococcus aureus Infection Models

Authors :
Gerben M. Franssen
Tom W. J. Scheenen
Massis Krekorian
Carl G. Figdor
Erik H.J.G. Aarntzen
Sandra Heskamp
Andor Veltien
Ingrid Jolanda Monique De Vries
Mangala Srinivas
René Raavé
Annemarie Kip
Kimberley R.G. Cortenbach
Nicolaas Koen van Riessen
Milou Boswinkel
Source :
Cancers, 13, 20, Cancers, Cancers; Volume 13; Issue 20; Pages: 5069, Cancers, Vol 13, Iss 5069, p 5069 (2021), Cancers, 13
Publication Year :
2021

Abstract

Simple Summary Immune cells are increasingly used for therapy in cancer and other diseases. To better understand immune-cell kinetics, cell-tracking with highly sensitive imaging modalities is required. The aim of this study was to develop a new strategy for the in vivo tracking of a small number of cells, using positron emission tomography (PET). We labeled poly(lactic-co-glycolic acid) nanoparticles containing a primary endcap (PLGA-NH2) with the radionuclide zirconium-89. The nanoparticles were characterized for size, polydispersity index, zetapotential and radiolabel retention. Subsequently, they were used for the ex vivo radiolabeling of a monocyte cell line (THP-1). We demonstrated that these radiolabeled monocyte cells can be traced in vivo in mouse tumor and infection models. Abstract The exponential growth of research on cell-based therapy is in major need of reliable and sensitive tracking of a small number of therapeutic cells to improve our understanding of the in vivo cell-targeting properties. 111In-labeled poly(lactic-co-glycolic acid) with a primary amine endcap nanoparticles ([111In]In-PLGA-NH2 NPs) were previously used for cell labeling and in vivo tracking, using SPECT/CT imaging. However, to detect a low number of cells, a higher sensitivity of PET is preferred. Therefore, we developed 89Zr-labeled NPs for ex vivo cell labeling and in vivo cell tracking, using PET/MRI. We intrinsically and efficiently labeled PLGA-NH2 NPs with [89Zr]ZrCl4. In vitro, [89Zr]Zr-PLGA-NH2 NPs retained the radionuclide over a period of 2 weeks in PBS and human serum. THP-1 (human monocyte cell line) cells could be labeled with the NPs and retained the radionuclide over a period of 2 days, with no negative effect on cell viability (specific activity 279 ± 10 kBq/106 cells). PET/MRI imaging could detect low numbers of [89Zr]Zr-THP-1 cells (10,000 and 100,000 cells) injected subcutaneously in Matrigel. Last, in vivo tracking of the [89Zr]Zr-THP-1 cells upon intravenous injection showed specific accumulation in local intramuscular Staphylococcus aureus infection and infiltration into MDA-MB-231 tumors. In conclusion, we showed that [89Zr]Zr-PLGA-NH2 NPs can be used for immune-cell labeling and subsequent in vivo tracking of a small number of cells in different disease models.

Details

ISSN :
20726694
Database :
OpenAIRE
Journal :
Cancers, 13, 20, Cancers, Cancers; Volume 13; Issue 20; Pages: 5069, Cancers, Vol 13, Iss 5069, p 5069 (2021), Cancers, 13
Accession number :
edsair.doi.dedup.....b2f9be72d4b7d562ecd5a573f79e51cd
Full Text :
https://doi.org/10.3390/cancers13205069